Brief: PLx Pharma Q2 Loss Per Share $0.66
14/08/2020 12:56
Aug 14 (Reuters) - PLx Pharma Inc PLXP.O :
* . REPORTS SECOND QUARTER 2020 RESULTS AND PROVIDES
BUSINESS
UPDATE
* Q2 LOSS PER SHARE $0.66
* TARGETING LAUNCH OF VAZALORE 325 MG AND 81 MG FOR Q3 2021
* SHIFTING DATE OF SNDA FILINGS FOR VAZALORE 325 MG AND 81
MG
DOSES EARLIER TO MID-NOVEMBER 2020
Source text for Eikon: ID:nGNX9nTnvT
Further company coverage: PLXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PLx Pharma Winddown
See all newsAustralia's Pilbara Minerals jumps on Pilgangoora lithium resource upgrade
Brief: Plx Pharma Winddown Terminated Employment Of Natasha Giordano, President And CEO, And Rita O'connor, CFO
Brief: PLx Pharma Inc. Enters Into A Stalking Horse Asset Purchase Agreement To Sell Vazalore And Substantially All Of Its Assets
U.S. STOCKS ON THE MOVE-HeartCore, Freight Technologies, MongoDB
Brief: Plx Pharma Inc. Receives Nasdaq Delisting Notice